

Open Peer Review on Qeios

Anti-LAG-3 Monoclonal Antibody Sym022

National Cancer Institute

Source

National Cancer Institute. <u>Anti-LAG-3 Monoclonal Antibody Sym022</u>. NCI Thesaurus. Code C156177.

A recombinant, human Fc-inert monoclonal antibody targeting lymphocyte-activation gene 3 protein (LAG-3; LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, monoclonal antibody Sym022 binds to human LAG-3 and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHCII) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHCII binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Additionally, Sym022 decreases LAG-3 surface levels through internalization and shredding. LAG-3 plays a key role in the activation of T-cells and natural killer (NK) cells.

Qeios ID: 9CXL4Z · https://doi.org/10.32388/9CXL4Z